World's Best Scientists 2026 revealed!
Constance Delaugerre

Constance Delaugerre

D-Index & Metrics

Immunology

D-Index
53
Citations
12321
World Ranking
3956
National Ranking
188

Constance Delaugerre publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Constance Delaugerre sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 324 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Constance Delaugerre D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Constance Delaugerre sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 53 D-Index — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Constance Delaugerre is affiliated with Université Paris Cité in France and has contributed extensively to research in the field of Medicine, particularly focusing on Infectious Diseases, Epidemiology, Virology, Hepatology, and Molecular Biology.

The scientist has been involved in studies covering several major research topics, including:

  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • SARS-CoV-2 and COVID-19 Research
  • SARS-CoV-2 detection and testing
  • COVID-19 Clinical Research Studies
  • Hepatitis B Virus Studies
  • HIV/AIDS drug development and treatment

Constance Delaugerre's publication record includes frequent contributions to several journals with multiple publications, such as:

  • bioRxiv (Cold Spring Harbor Laboratory) - 11 publications
  • Open Forum Infectious Diseases - 9 publications
  • Journal of Antimicrobial Chemotherapy - 7 publications
  • Clinical Infectious Diseases - 5 publications
  • Journal of Clinical Virology - 5 publications

Recent notable papers authored or coauthored by Delaugerre cover topics related to antiviral therapies, diagnostic assays, and viral immunology. Some of these are:

  • No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection (2020, Médecine et Maladies Infectieuses)
  • Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs (2020, Journal of Clinical Microbiology)
  • SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4 (2021, The Journal of Experimental Medicine)
  • Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study (2022, The Lancet HIV)
  • Mpox in people with past infection or a complete vaccination course: a global case series (2023, The Lancet Infectious Diseases)

Delaugerre's frequent coauthors include:

  • Jean-Michel Molina
  • Audrey Gabassi
  • Marie-Laure Chaix
  • Jérôme Le Goff
  • Maud Salmona

Their combined work spans a broad range of infectious disease research, with particular attention to HIV/AIDS, viral infections, and antiviral treatments. Collaboration within this network contributes to an interdisciplinary approach, integrating clinical virology, epidemiological methods, and molecular biology techniques.

Best Publications

  • On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

    Abstr Act;C. Capitant;B. Spire;G. Pialoux

  • No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.

    J.M. Molina;C. Delaugerre;J. Le Goff;B. Mela-Lima

  • Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy

    D Descamps;P Flandre;V Calvez;G Peytavin

  • Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

    Jean-Michel Molina;Jean-Michel Molina;Isabelle Charreau;Bruno Spire;Laurent Cotte

  • Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

    Jean-Michel Molina;Isabelle Charreau;Christian Chidiac;Gilles Pialoux

  • Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1).

    Roland Tubiana;Roland Tubiana;Jerome Le Chenadec;Jerome Le Chenadec;Christine Rouzioux;Christine Rouzioux;Laurent Mandelbrot

  • Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs.

    Sidonie Lambert-Niclot;Alexis Cuffel;Samuel Le Pape;Christelle Vauloup-Fellous

  • Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

    Pierre-Louis Tharaux;Gilles Pialoux;Arthur Pavot;Xavier Mariette

  • Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.

    Guislaine Carcelain;Roland Tubiana;Assia Samri;Vincent Calvez

  • Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

    Jean-François Delfraissy;Philippe Flandre;Constance Delaugerre;Jade Ghosn

  • Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting.

    Juliette Pavie;Anne Rachline;Bénédicte Loze;Laurence Niedbalski

  • Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

    C. Delaugerre;R. Rohban;A. Simon;M. Mouroux

  • Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

    Anne-Geneviève Marcelin;Constance Delaugerre;Marc Wirden;Pedro Viegas

  • Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.

    Unknown

  • Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.

    Yves Lévy;Rodolphe Thiébaut;Matthieu Montes;Matthieu Montes;Christine Lacabaratz;Christine Lacabaratz

  • SARS-CoV-2 induces human plasmacytoid predendritic cell diversification via UNC93B and IRAK4.

    Fanny Onodi;Lucie Bonnet-Madin;Laurent Meertens;Léa Karpf

  • Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial

    Beatriz Grinsztejn;Nathalie De Castro;Vincent Arnold;Valdiléa G Veloso

  • Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients

    Constance Delaugerre;Constance Delaugerre;Sébastien Gallien;Sébastien Gallien;Philippe Flandre;Philippe Flandre;Dominique Mathez

  • A Global Interactome Map of the Dengue Virus NS1 Identifies Virus Restriction and Dependency Host Factors

    Mohamed Lamine Hafirassou;Laurent Meertens;Claudia Umaña-Diaz;Athena Labeau

  • Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

    Anne-Geneviève Marcelin;Claire Lamotte;Constance Delaugerre;Nadine Ktorza

  • Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients.

    Anders Boyd;Karine Lacombe;Fabien Lavocat;Sarah Maylin

  • Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.

    Marie-Laure Chaix;Diane Descamps;Marc Wirden;Laurence Bocket

  • Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).

    Christine Katlama;Stéphanie Dominguez;Karine Gourlain;Claudine Duvivier

Frequent Co-Authors

Jean-Michel Molina
Jean-Michel Molina Université Paris Cité
Marie-Laure Chaix
Marie-Laure Chaix Université Paris Cité
Anne-Geneviève Marcelin
Anne-Geneviève Marcelin Sorbonne University
Karine Lacombe
Karine Lacombe Hôpital Saint-Antoine
François Simon
François Simon Université Paris Cité
Laurence Meyer
Laurence Meyer University of Paris-Saclay
Jade Ghosn
Jade Ghosn Hôpital Bichat - Claude-Bernard (Hôpitaux Universitaires Paris Nord Val de Seine)
Vincent Calvez
Vincent Calvez Centre national de la recherche scientifique, CNRS

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to diverse healthcare careers, many of which intersect with nursing and mental health fields. For those interested in nursing, exploring easy LPN programs to get into can be a practical starting point. Licensed Practical Nurse (LPN) programs offer foundational clinical skills that complement immunological knowledge, especially in patient care and infection control.

Advancing further, students might consider pursuing easier pathways to higher qualifications, such as the easiest NP program. Nurse Practitioners (NPs) with a background in immunology can specialize in areas requiring a deep understanding of immune responses and disease management.

For those passionate about mental health and immunology's role in neuroinflammation, the best psychiatric mental health nurse practitioner programs online provide excellent clinical placement opportunities to gain hands-on experience. Combining mental health with immunology knowledge can lead to innovative approaches in treating psychiatric disorders.

Cost is always a factor, and students may want to review the cheapest PMHNP programs to find affordable options without compromising quality. These programs help build critical skills for a career at the intersection of immune system research and psychiatric care.

Best Scientists Citing Constance Delaugerre

Trending Scientists

Recently Published Articles